BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial

Reuters10-24

Oct 24 (Reuters) - Aprea Therapeutics Inc APRE.O:

APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051
APREA THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OR UNEXPECTED SAFETY ISSUES REPORTED
APREA THERAPEUTICS INC - DOSE ESCALATION CONTINUES WITH 150 MG COHORT ENROLLMENT

Source text: ID:nGNX2ZzVxr

Further company coverage: APRE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577751674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577751674","market":"nz","top_or_hot":-1,"title":"BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial</title></head><body><p><span>Oct 24 (Reuters)</span><span> - </span>Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051</p></li><li><p>APREA THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OR UNEXPECTED SAFETY ISSUES REPORTED</p></li><li><p>APREA THERAPEUTICS INC - DOSE ESCALATION CONTINUES WITH 150 MG <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> ENROLLMENT</p></li></ul><p>Source text: <span>ID:nGNX2ZzVxr</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial</title></head><body><p><span>Oct 24 (Reuters)</span><span> - </span>Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051</p></li><li><p>APREA THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OR UNEXPECTED SAFETY ISSUES REPORTED</p></li><li><p>APREA THERAPEUTICS INC - DOSE ESCALATION CONTINUES WITH 150 MG <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> ENROLLMENT</p></li></ul><p>Source text: <span>ID:nGNX2ZzVxr</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA59XSC8:1","article_id":"2577751674","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577751674","pubTimestamp":1761309742,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 TrialOct 24 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIV","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APRE":"Aprea Therapeutics, Inc."},"translate_title":"简介-Aprea在APR-1051 Wee1试验中看到早期活动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 TrialOct 24 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIVITY FOR WEE1 KINASE INHIBITOR APR-1051APREA THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OR UNEXPECTED SAFETY ISSUES REPORTEDAPREA THERAPEUTICS INC - DOSE ESCALATION CONTINUES WITH 150 MG COHORT ENROLLMENTSource text: ID:nGNX2ZzVxrFurther company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577751674","isCrawlerRequest":true}